Apricus Biosciences Inc news

   Watch this stock
Showing stories 1 - 10 of about 30   

Articles published

APRI 1.88 0.00 (0.00%)
price chart
Apricus Biosciences: A Screaming Buy Or A Falling Knife?
Apricus Biosciences, Inc. (NASDAQ:APRI) recently began their launch of Vitaros, a topical treatment for Erectile Dysfunction (NYSE:ED), with availability in the UK, Sweden, and now Germany.
Apricus Biosciences ED Treatment Vitaros Now in Germany
Apricus Biosciences, Inc. (APRI - Snapshot Report) announced the launch of its sole approved product, Vitaros in Germany.
Apricus Biosciences' ED Treatment Vitaros Now in Germany - Analyst Blog  NASDAQ
Apricus Biosciences Announces the Launch of Its Topical Treatment for ...  Wall Street Journal
Related articles »  
Apricus Biosciences Provides Corporate Update and Second Quarter 2014 ...
SAN DIEGO, Aug. 12, 2014 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines to meet the needs of patients, today provided a corporate update and reported financial results for ...
Apricus Biosciences Enters Into Common Stock Purchase Agreement With ...  The Wall Street Transcript
Related articles »  
Apricus Biosciences Announces Corporate Update and Second Quarter 2014 ...
Apricus Biosciences, Inc. APRI, +1.64% a pharmaceutical company focusing on the development and commercialization of novel therapeutics for men's and women's health, today announced that the Company's second quarter financial results will be ...
Related articles »  
Apricus Biosciences Continues To Deliver In Spite Of Bearish Pressures (APRI)
Apricus Biosciences, Inc. (NASDAQ:APRI) announced the second successful launch of its Erectile Dysfunction (NYSE:ED) treatment, Vitaros, in Sweden by its partner Sandoz.
Related articles »  
Apricus Biosciences to Present at the Canaccord Genuity 34th Annual Growth ...
SAN DIEGO, Aug. 6, 2014 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a pharmaceutical company focusing on the development and commercialization of novel therapeutics for men's and women's health, today announced that Richard ...
Related articles »  
Apricus Biosciences Announces Multi-Year Partnership With the Scleroderma ...
SAN DIEGO, Aug. 8, 2014 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a pharmaceutical company focusing on the development and commercialization of novel therapeutics for men's and women's health, today announced a multi-year ...
Apricus Biosciences Signs Partnership With Scleroderma Research Foundation  RTT News
Related articles »  
Apricus Biosciences Upgraded by Zacks to "Neutral" (APRI)
Apricus Biosciences, Inc, formerly NexMed, Inc, is a pharmaceutical research and development company focused on the design and development of products and technologies in multiple therapeutic areas, including oncology, sexual dysfunction, autoimmune ...
Related articles »  
Hot Stocks : Apricus Biosciences (NASDAQ:APRI), Novogen Limited (NASDAQ ...
On Friday Apricus Biosciences, Inc. (NASDAQ:APRI) share price closed at $1.88. Company return on equity (ROE) is -213.30%.
Related articles »  
Morning Alert: NTT DOCOMO (NYSE:DCM), Apricus Biosciences (NASDAQ ...
Apricus Biosciences, Inc. (NASDAQ:APRI), a pharmaceutical company focusing on the development and commercialization of novel therapeutics for men's and women's health, on 16 June announced the launch of Vitaros(R), Apricus' novel topical ...
Related articles »